ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 032,12
0,94%
Dow Jones
38 675,68
0,00%
DAX
18 194,82
1,12%
Brent Oil
83,375
0,30%
Bitcoin
63 885,83
-0,18%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Immix Biopharma Inc (IMMX)

  7. Immix Biopharma Inc (IMMX) Actualités

IMMX Immix Biopharma Inc

2,35
0,00 (0,00%)
Avant marché
Dernière mise à jour : 11:53:45
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Immix Biopharma Inc IMMX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 2,35 11:53:45
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,35
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
07/2/202423:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/2/202415:09EDGAR2Form 8-K - Current report
05/2/202422:38EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/2/202422:37EDGAR2Form 8-K - Current report
13/12/202300:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202316:48IHNWImmix Biopharma Announces FDA Approval of IND Application..
10/11/202301:57EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
25/9/202322:15EDGAR2Form S-3 - Registration statement under Securities Act of..
19/9/202301:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/9/202300:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202322:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/8/202322:15EDGAR2Form SC 13D - General statement of acquisition of beneficial..
23/8/202322:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/8/202322:05EDGAR2Form 8-K - Current report
14/8/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/8/202322:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
25/7/202314:42GLOBEImmix Biopharma Subsidiary Nexcella Announces NXC-201..
17/7/202315:37GLOBEImmix Biopharma Reports 2nd Positive Interim Clinical Trial..
14/7/202323:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/7/202323:26EDGAR2Form 8-K - Current report
10/7/202315:47GLOBEImmix Biopharma Subsidiary Nexcella Completes Initial..
26/6/202315:49GLOBEImmix Biopharma Subsidiary Nexcella Completes Pre-IND..
22/6/202315:53GLOBEImmix Biopharma Subsidiary Nexcella Appoints Edward J...
20/6/202315:45GLOBEImmix Biopharma Subsidiary Nexcella Appoints Jeffrey H...
16/6/202315:43GLOBEImmix Biopharma Subsidiary Nexcella Appoints Mary Sue..
14/6/202313:30GLOBEImmix Biopharma Completes $5 Million At-The-Market Equity..
12/6/202315:49GLOBEImmix Biopharma Subsidiary Nexcella Appoints Henry..
26/5/202315:53GLOBEImmix Biopharma Subsidiary Nexcella Announces Commencement..
21/5/202322:05GLOBENexcella Announces Positive NXC-201 Clinical Results at..
21/5/202322:00GLOBEImmix Biopharma Announces Positive NXC-201 Clinical Results..

Dernières Valeurs Consultées

NASDAQ
IMMX
Immix Biopharma
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés